Intercept Pharmaceuticals Inc. (Nasdaq: ICPT) reported upbeat results from a midstage clinical trial of its liver disease treatment. The stock price leaped $39.34 to close at $276.52.
Upbeat trial results for Intercept Pharmaceuticals
August 12, 2014 at 17:05 PM EDT
